Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation
- PMID: 11349722
- DOI: 10.1097/00007890-200104150-00012
Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation
Abstract
Background: Lipoatrophic diabetes is an insulin resistance syndrome characterized by the complete or partial lack of adipose tissue and disturbances in lipid and glucose metabolism. Nonalcoholic steatohepatitis (NASH) is a well-described change in liver pathology consisting of steatosis, hepatitis, and fibrosis that can be associated with lipoatrophic diabetes.
Results: This article describes the first reported case of lipoatrophic diabetes with NASH leading to liver failure and liver transplantation. Before transplantation, the patient required 600-700 U of insulin/day. After transplantation, a dramatic decline in her insulin requirements was observed, despite corticosteroids. Eighteen months after transplantation, her glycemic control worsened, and she developed recurrent NASH on serial liver biopsies.
Conclusions: NASH associated with lipoatrophic diabetes can recur after liver transplantation, and in this case, was accompanied by increased insulin requirements. These results suggest that the development of NASH itself may contribute to the insulin resistance observed in lipoatrophic diabetes.
Similar articles
-
Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease.Liver Transpl. 2001 Jul;7(7):608-14. doi: 10.1053/jlts.2001.25453. Liver Transpl. 2001. PMID: 11460228
-
Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis.Liver Transpl. 2009 Dec;15(12):1843-51. doi: 10.1002/lt.21943. Liver Transpl. 2009. PMID: 19938117
-
Characteristics and risk factors for recurrence of nonalcoholic steatohepatitis following liver transplantation.Scand J Gastroenterol. 2019 Feb;54(2):233-239. doi: 10.1080/00365521.2019.1577484. Epub 2019 Apr 18. Scand J Gastroenterol. 2019. PMID: 30999770
-
[NASH -- nonalcoholic steatohepatitis].Z Gastroenterol. 2003 Jan;41(1):77-90. doi: 10.1055/s-2003-36679. Z Gastroenterol. 2003. PMID: 12541180 Review. German.
-
Nonalcoholic steatohepatitis and the metabolic syndrome.Metab Syndr Relat Disord. 2008 Mar;6(1):1-7. doi: 10.1089/met.2007.0026. Metab Syndr Relat Disord. 2008. PMID: 18370830 Review.
Cited by
-
Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial.Eur J Endocrinol. 2013 Apr 15;168(5):771-8. doi: 10.1530/EJE-12-0969. Print 2013 May. Eur J Endocrinol. 2013. PMID: 23447519 Free PMC article. Clinical Trial.
-
Pathogenesis and management issues for non-alcoholic fatty liver disease.World J Gastroenterol. 2007 Sep 14;13(34):4539-50. doi: 10.3748/wjg.v13.i34.4539. World J Gastroenterol. 2007. PMID: 17729403 Free PMC article. Review.
-
Effects of Metreleptin in Pediatric Patients With Lipodystrophy.J Clin Endocrinol Metab. 2017 May 1;102(5):1511-1519. doi: 10.1210/jc.2016-3628. J Clin Endocrinol Metab. 2017. PMID: 28324110 Free PMC article.
-
The impact of post-transplant diabetes mellitus on liver transplant outcomes.Clin Transplant. 2019 Jun;33(6):e13554. doi: 10.1111/ctr.13554. Epub 2019 Apr 23. Clin Transplant. 2019. PMID: 30927288 Free PMC article. Clinical Trial.
-
Lipodystrophy Due to Adipose Tissue-Specific Insulin Receptor Knockout Results in Progressive NAFLD.Diabetes. 2016 Aug;65(8):2187-200. doi: 10.2337/db16-0213. Epub 2016 May 10. Diabetes. 2016. PMID: 27207510 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical